Survodutide's second underwhelming phase 3 read-out knocks Zealand's shares
- Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3.
- Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out.
- Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question.
- It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.
💡 Points
The efficacy sits between semaglutide 2.4 mg and top-dose tirzepatide, but timing is brutal: Lilly's amylin combination landed 24 hours earlier at a far higher weight-loss level. With roughly one in five patients dropping out on GI effects, survodutide's remaining angle is MASH, where glucagon activity is the differentiator, not raw weight loss. Expect investors to price Zealand on that liver story and on how Boehringer positions dosing and titration.
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 ↗